- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02138864
Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
With the urbanization of Taiwanese society, there are increasing numbers of people committing suicide by charcoal burning, making carbon monoxide (CO) encephalopathy a new pandemic phenomenon. In CO related parkinsonism, the clinical features included gait disturbances, mask face, rigidities and small steps. From literature searches, the CO related parkinsonism is related to white matter damages or decline in dopamine innervations. From our previous research results, the CO related neuronal damages would started from reversible or progressive white matter demyelination. For some patients, axonopathy or gray matter atrophy developed and became irreversible. The neuronal networks in determining development of Parkinsonism required to be established.
In terms of neurotransmitter, most of the clinical data for Parkinsonism came from studies of idiopathic Parkinson's disease while the data of CO related Parkinsonism were limited to case reports. From neuropathology studies in idiopathic Parkinson's disease, dopamine deficits and decreased in monoamine transporters were observed well before the development of clinical features. Although there is linkage between CO related Parkinsonism and dopamine deficits, patients with CO intoxication had poor response to levodopa. The observation suggested the critical networks and neurotransmitters were still not well understood.
18F-FP-(+)-DTBZ is a newly developed nuclear medicine tracer for monoamine transporter. The study purpose is to determine the clinical values of 18F-FP-(+)-DTBZ in the diagnosis of Parkinsonism in patients with carbon monoxide intoxication, regional distribution and its correlation with clinical parameters. This is a three-year prospective research. For each patient, the PET will be arranged twice, with an interval of 18 months. The regional distribuation of 18F-FP-(+)-DTBZ in relation to Parkinsonism severity and regional reduction patterns longitudially will be assessed in order to understand the regional neurotoxicity and the functional progression.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan, 886
- Chang Gung Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Male or female age 20 years to 65 years.
- Patients group should fulfilled diagnostic criteria of carbon monoxide intoxication
- Patients who provide a written informed consent prior to study entry. If the patient is incapable of informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm consent)
Exclusion criteria
- History of developmental disorders, agitated mood or a confused state that prevented either a neuropsychiatric interview or neuroimaging.
- Unable to stay still in the PET scanner for 30 minutes.
- History or presence of QTc prolongation. (>500msec)
- Pregnancy and breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-FP-(+)-DTBZ only
PET tracer: 18F-FP-(+)-DTBZ
|
no available
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the regional decline in 18F-DTBZ uptake of Parkinsonism after carbon monoxide intoxication
Time Frame: up to 3 years
|
This study will assess the brain uptake and distribution of 18F-DTBZ in 25 carbon monoxide intoxication patients with Parkinsonism.
For each patient, the PET will be arranged twice, with an interval of 1.5 years.
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chiung-Chih Chang, M.D.; Ph.D, Chang Gung Memorial Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101-4350A
- CDE102IND01009 (Registry Identifier: CHIUNH-CHIH CHANG)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carbon Monoxide-induced Parkinsonism
-
Rigshospitalet, DenmarkCompletedCarbon Monoxide Poisoning From Fire AccidentsDenmark
-
Nonin Medical, IncCompleted
-
Johns Hopkins Bloomberg School of Public HealthBrown University; National Institutes of Health (NIH); Universidad Peruana Cayetano... and other collaboratorsCompletedRespiratory Conditions Due to Other External Agents | Poisoning by Carbon Monoxide From Domestic FuelsKenya, Nepal, Peru
-
Paul G. Harch, M.D.Harch Hyperbaric Research FoundationUnknownNeuropsychiatric Sequelae of Carbon Monoxide PoisoningUnited States
-
Liaocheng People's HospitalUnknownDelayed Encephalopathy After Carbon Monoxide PoisoningChina
-
Intermountain Health Care, Inc.Recruiting
-
Intermountain Health Care, Inc.Enrolling by invitation
-
Ankara City Hospital BilkentRecruitingCarbon Monoxide PoisoningTurkey
-
Nonin Medical, IncTerminated
-
Nonin Medical, IncCompleted
Clinical Trials on 18F-FP-(+)-DTBZ
-
Yale UniversityPfizer; Avid RadiopharmaceuticalsCompletedDiabetes Mellitus, Type 1United States
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalCompleted
-
Columbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnDiabetes Mellitus, Type 1 | Healthy VolunteersUnited States
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompletedVascular ParkinsonismTaiwan
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompleted
-
Chang Gung Memorial HospitalCompletedParkinson's DiseaseTaiwan
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompletedParkinson's DiseaseTaiwan
-
Chang Gung Memorial HospitalCompleted
-
National Institute of Neurological Disorders and...CompletedCervical Dystonia | Dystonia | Focal Dystonia | Movement DisorderUnited States